Efficacy of Metformin Therapy in Management of Polycystic Ovary Syndrome
Abstract
Background: Earlier analysis shows that metformin is beneficial clinically in treating polycystic ovary syndrome (PCOS) by reducing hyperinsulinemia. Aim: The goal of this study was to determine the importance of metformin in modifying amenorrhea/ oligomenorrhea and anovulation within six months in women with polycystic ovary syndrome and hyperinsulinemia. Another goal was to evaluate hyperinsulinemia and weight loss with metformin in the studied people. Methods: This randomized controlled trial was held at the Obstetrics and Gynecology department of the Jinnah Postgraduate Medical Centre Karachi for one-year duration from July 2020 to July 2021. The study included 160 women who met the biochemical and clinical conditions for hyperinsulinemia and PCOS. Two females stopped taking the drug due to abdominal cramps, diarrhoea and nausea. Other excluding factors were inadequate adherence in one female women and use of other medications in two women. One female had anomalous levels of serum creatinine and was omitted from the analysis. So, 154 total patients were studied. 500 mg / day metformin orally was started and was held at 500 mg for six-months. FSH, serum LH, fasting insulin, fasting glucose and creatinine were measured in addition to ultrasound and body weight. After 6 months: fasting insulin levels, menstrual cycles, body weight and serum progesterone on day 21 were measured. Serum androgen levels remains high in PCOS along with Prolactin levels and the LH/FSH ratio may…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 160 participants or records.
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.